Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2satraplatin 1ixazomib 1X-Rays 1Valproic Acid 1Trastuzumab 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1Capecitabine 1Albumin-Bound Paclitaxel 1AH 111585 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancers × ixazomib × Clear all
NCT02042989 2022-07-11

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
68 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡